Mipsagargin
Alternative Names: G-202; Thapsigargin prodrugLatest Information Update: 03 Aug 2022
At a glance
- Originator Johns Hopkins University
- Developer National Cancer Institute (USA); Rebus Holdings; University of Texas Health Science Center at Houston
- Class Antineoplastics; Drug conjugates; Lactones; Peptides; Sesquiterpenes
- Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer; Gastric cancer; Glioblastoma; Liver cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
Most Recent Events
- 31 Dec 2021 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA (IV)
- 31 Dec 2021 Discontinued - Phase-II for Glioblastoma (Recurrent, Second-line therapy or greater) in USA (IV)
- 31 Dec 2021 Discontinued - Phase-II for Liver cancer (Late-stage disease, Second-line therapy or greater) in USA (IV)